17β-HSD1 and STS inhibitors

Details 17β-HSD1 and STS inhibitors 17β-HSD1 and STS inhibitors

2006-05-26

2011-10-04

Badio, Barbara P (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S176000, C540S054000, C552S500000, C552S539000, C552S627000

Reexamination Certificate

active

08030298

ABSTRACT:
The present invention relates to novel substituted steroid derivatives which represent selective inhibitors of the 17β-hydroxysteroid dehydrogenase type I (17β-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17β-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17β-estradiol concentration.

REFERENCES:
patent: 3275623 (1966-09-01), Knox
patent: 3347878 (1967-10-01), Boswell
patent: 3413321 (1968-11-01), Boswell
patent: 5204337 (1993-04-01), Labrie et al.
patent: 6043236 (2000-03-01), Brattsand et al.
patent: 2003/0170292 (2003-09-01), Young et al.
patent: 2005/0192263 (2005-09-01), Messinger et al.
patent: 2006/0009434 (2006-01-01), Hillisch et al.
patent: 2006/0052461 (2006-03-01), Hillisch et al.
patent: 0 367 576 (1990-05-01), None
patent: WO 93/05063 (1993-03-01), None
patent: WO 93/05064 (1993-03-01), None
patent: WO 96/15257 (1996-05-01), None
patent: WO 96/28462 (1996-09-01), None
patent: WO 99/50453 (1999-10-01), None
patent: WO 00/07996 (2000-02-01), None
patent: WO 02/32409 (2002-04-01), None
patent: WO 03/017973 (2003-03-01), None
patent: WO 2004/080271 (2004-09-01), None
patent: WO 2004/085345 (2004-10-01), None
patent: WO 2004/085457 (2004-10-01), None
patent: WO 2004/085459 (2004-10-01), None
patent: WO 2005/047303 (2005-05-01), None
patent: WO 2006/003012 (2006-01-01), None
patent: WO 2006/003013 (2006-01-01), None
patent: WO 2006/027347 (2006-03-01), None
Akanni et al., “Preparation of 16-formylestradiol and the 16-(α-methylenebutanolide) derivative”, Steroids, May 1993, vol. 58, pp. 234-238.
Cushman et al., “Synthesis, Antitubulin and Antimitotic Activity, and Cytotoxicity of Analogs of 2-Methoxyestradiol, an Endogenous Mammalian Metabolite of Estradiol That Inhibits Tubulin Polymerization by Binding to the Colchicine Binding Site”, Journal of Medicinal Chemistry, 1995, vol. 38, No. 12, pp. 2041-2049.
Cushman et al., “The Effect of Exchanging Various Substituents at the 2-Position of 2-Methoxyestradiol on Cytotoxicity in Human Cancer Cell Cultures and Inhibition of Tubulin Polymerization”, Journal of Medicinal Chemistry, 2002, vol. 45, No. 21, pp. 4748-4754.
Day et al., “The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells”, Journal of Steroid Biochemistry & Molecular Biology, 2003, vol. 84, pp. 317-325.
Edwards et al., “Difluoromethyldiphenylphosphine Oxide. A New Reagent for Conversion of Carbonyl Compounds to 1,1-Difluoroolefins”, Tetrahedron Letters, 1990, vol. 31, No. 39, pp. 5571-5574.
González et al., “Synthesis and Pharmacological Evaluation of 8α-Estradiol Derivatives”, Steroids, Aug. 1982, vol. 40, No. 2, pp. 171-187.
Koffman et al., “Evidence for Involvement of Tyrosine in Estradiol Binding by Rat Uterus Estrogen Receptor”, Journal of Steroid Biochemistry & Molecular Biology, 1991, vol. 38, No. 2, pp. 135-139.
Labaree et al., “Synthesis and Evaluation of B-, C-, and D-Ring-Substituted Estradiol Carboxylic Acid Esters as Locally Active Estrogens”, Journal of Medicinal Chemistry, 2003, vol. 46, No. 10, pp. 1886-1904.
Labrie et al., “The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology”, Steroids, Jan. 1997, vol. 62, pp. 148-158.
Lawrence et al., “Novel and Potent 17β-Hydroysteroid Dehydrogenase Type 1 Inhibitors”, Journal of Medicinal Chemistry, 2005, vol. 48, No. 8, pp. 2759-2762.
Ley et al., “Tetrapropylammonium Perruthenate, Pr4N+RuO4-, TPAP: A Catalytic Oxidant for Organic Synthesis”, Synthesis, Jul. 1994, pp. 639-666.
Liu et al., “Synthesis of High Affinity Fluorine-Substituted Ligands for the Androgen Receptor. Potential Agents for Imaging Prostatic Cancer by Positron Emission Tomography”, Journal of Medicinal Chemistry, 1992, vol. 35, No. 11, pp. 2113-2129.
Lunn et al., “The Adamantyl Carbonium Ion as a Dehydrogenating Agent, Its Reactions with Estrone”, Tetrahedron, 1968, vol. 24, pp. 6773-6776.
Mindnich et al., “The role of 17 beta-hydroxysteroid dehydrogenases”, Molecular and Cellular Endocrinology, 2004, vol. 218, pp. 7-20.
Mohanakrishnan et al., “Pd(0)-Mediated Cross Coupling of 2-lodoestradiol with Organozinc Bromides: A General Route to the Synthesis of 2-Alkynyl, 2-Alkenyl and 2-Alkylestradiol Analogs”, Synlett, 1999, No. 07, pp. 1097-1099.
Nambara et al., “Syntheses of Estetrol Monoglucuronides1”, Steroids, Jan. 1976, vol. 27, No. 1, pp. 111-122.
Nussbaumer et al., “Steroid sulfatase inhibitors”, Expert Opin. Ther. Patents, 2003, vol. 13, No. 5, pp. 605-625.
Nussbaumer et al., “Steroid Sulfatase Inhibitors”, Medicinal Research Reviews, 2004, vol. 24, No. 4, pp. 529-576.
Oda et al., “The Hydrogenation of α-Hydroxymethylene-ketone Derivatives to α-Hydroxymethylene-ketone Derivatives with a Cell-Free System ofStreptomyces cinereocrocatus”, Chem. Pharm. Bull., 1989, vol. 37, No. 2, pp. 502-505.
Page et al., “Efficient Regioselective A-Ring Functionalization of Oestrogens”, Tetrahedron, 1990, vol. 46, No. 6, pp. 2059-2068.
Pelletier et al., “Synthesis and Evaluation of Estradiol Derivatives With 16α-(Bromoalkylamide), 16α-(Bromoalkyl) or 16α-(Bromoalkynyl) Side Chain as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 Without Estrogenic Activity”, Bioorganic & Medicinal Chemistry, 1996, vol. 4, No. 10, pp. 1617-1628.
Poirier, “Inhibitors of 17β-Hydroxysteroid Dehydrogenases”, Current Medicinal Chemistry, 2003, vol. 10, No. 6, pp. 453-477.
Poirier et al., “Synthesis of 17β-Estradiol Derivatives with N-Butyl, N-Methyl Alkylamide Side Chain at Position 15”, Tetrahedron, 1991, vol. 47, No. 37, pp. 7751-7766.
Poirier et al., “D-Ring Alkylamide Derivatives of Estradiol: Effect on ER-Binding Affinity and Antiestrogenic Activity”, Bioorganic & Medicinal Chemistry Letters, 1996, vol. 6, No. 21, pp. 2537-2542.
Poirer et al., “A 6β-(Thiaheptanamide) derivative of Estradiol as Inhibitor of 17β-Hydroxysteroid Dehydrogenase Type 1”, J. Steroid Biochem. Molec. Biol., 1998, vol. 64, pp. 83-90.
Puranen et al., “Site-directed mutagenesis of the putative active site of human 17β-hydroxysteroid dehydrogenase type 1”, Biochem. J., 1994, vol. 304, pp. 289-293.
Roa et al., “A new, pratical synthesis of 2-methoxyestradiols”, Steroids, 2002, vol. 67, pp. 1065-1070.
Reed et al., “Steroid Sulfatase: Molecular Biology, Regulation, and Inhibition”, Endocrine Reviews, 2005, vol. 26, No. 2, pp. 171-202.
Sam et al., “C16 and C17 Derivatives of Estradiol as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1: Chemical Synthesis and Structure-Activity Relationships”, Drug Design and Discovery, 1998, vol. 15, pp. 157-180.
Schneider et al., “A Convenient Method for the Formation of 16-Methylene-17-ketosteroids”, Synthesis, Aug. 1983, pp. 665-669.
Schwarz et al., “Studies on modified estrogens: Towards the synthesis of novel 14,15-cyclopropa[a]estra-1,3,5(10),8-tetraenes”, Pharmazie, 2001, vol. 56, No. 11, pp. 843-849.
Tamaya et al., “Comparison of Cellular Levels of Steroid Receptors in Uterine Leiomyoma and Myometrium”, Acta Obstet Gynecol Scand, 1985, vol. 64, pp. 30

Affiliated with

Also associated with

Rating

17β-HSD1 and STS inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 17β-HSD1 and STS inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 17β-HSD1 and STS inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4255463